{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T07:01:04Z","timestamp":1793689264934,"version":"4.5.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bjanaesthesia.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["British Journal of Anaesthesia"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.bja.2023.11.029","type":"journal-article","created":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T20:54:51Z","timestamp":1702068891000},"page":"457-460","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Pholcodine and allergy to neuromuscular blocking agents: where are we and how did we get here?"],"prefix":"10.1016","volume":"132","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2681-2288","authenticated-orcid":false,"given":"Louise","family":"Savic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8127-1739","authenticated-orcid":false,"given":"Philip M.","family":"Hopkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bja.2023.11.029_bib1","series-title":"New Zealand. Pholcodine: benefit-risk review","year":"2019"},{"key":"10.1016\/j.bja.2023.11.029_bib2","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1111\/j.1398-9995.2010.02518.x","article-title":"IgE-sensitisation to the cough suppressant pholcodine and the effects of its withdrawal from the Norwegian market","volume":"66","author":"Florvaag","year":"2011","journal-title":"Allergy"},{"key":"10.1016\/j.bja.2023.11.029_bib3","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1111\/all.13081","article-title":"Six years without pholcodine; Norwegians are significantly less IgE-sensitized and clinically more tolerant to neuromuscular blocking agents","volume":"72","author":"de Pater","year":"2017","journal-title":"Allergy"},{"key":"10.1016\/j.bja.2023.11.029_bib4","article-title":"Pholcodine consumption increases the risk of perioperative anaphylaxis to neuromuscular blocking agents: the ALPHO case-control study. [Preprint.]","author":"Mertes","year":"2022","journal-title":"medRxiv"},{"key":"10.1016\/j.bja.2023.11.029_bib5","unstructured":"Available from: www.ema.europa.eu\/en\/medicines\/human\/referrals\/pholcodine-containing-medicinal-products (accessed 21 March 2023). European Medicines Agency statement on withdrawal of pholcodine-containing products."},{"key":"10.1016\/j.bja.2023.11.029_bib6","unstructured":"Available from: www.tga.gov.au\/news\/media-releases\/pholcodine-cough-medicines-cancelled-tga-and-recalled-pharmacies-safety-reasons (accessed 21 March 2023). Australian Government Therapeutic Goods Administration statement on withdrawal of pholcodine-containing products"},{"key":"10.1016\/j.bja.2023.11.029_bib7","unstructured":"Available from: www.gov.uk\/government\/news\/safety-withdrawal-of-pholcodine-containing-cough-and-cold-medicines (accessed 21 March 2023). UK Medicines and Healthcare products Regulatory Agency statement on withdrawal of pholcodine-containing products"},{"key":"10.1016\/j.bja.2023.11.029_bib8","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/306262a0","article-title":"Substituted ammonium ions as allergenic determinants in drug allergy","volume":"306","author":"Baldo","year":"1983","journal-title":"Nature"},{"key":"10.1016\/j.bja.2023.11.029_bib9","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/j.1399-6576.2004.00591.x","article-title":"Prevalence of IgE antibodies to morphine. Relation to the high and low incidence of NMBA anaphylaxis in Norway and Sweden, respectively","volume":"5","author":"Florvaag","year":"2005","journal-title":"Acta Anaesthesiol Scand"},{"key":"10.1016\/j.bja.2023.11.029_bib10","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/j.1398-9995.2005.00933.x","article-title":"Pholcodine stimulates a dramatic increase in IgE in IgE-sensitised individuals. A pilot study","volume":"61","author":"Florvaag","year":"2006","journal-title":"Allergy"},{"key":"10.1016\/j.bja.2023.11.029_bib11","first-page":"127","article-title":"Allergic reactions during anesthesia \u2013 a national network for registration, diagnosis and follow-up","volume":"120","author":"Guttormsen","year":"2000","journal-title":"Tidsskr Nor Laegeforen"},{"key":"10.1016\/j.bja.2023.11.029_bib12","doi-asserted-by":"crossref","first-page":"E16","DOI":"10.1016\/j.bja.2019.01.027","article-title":"Comparative epidemiology of suspected perioperative hypersensitivity reactions","volume":"123","author":"Mertes","year":"2019","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.bja.2023.11.029_bib13","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.bja.2018.04.014","article-title":"Anaesthesia, surgery and life-threatening allergic reactions: epidemiology and clinical features of periperative anaphylaxis in the 6th National Audit Project","volume":"121","author":"Harper","year":"2018","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.bja.2023.11.029_bib14","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.jaci.2011.03.003","article-title":"Anaphylaxis during anaesthesia in France: an 8-year national survey","volume":"128","author":"Mertes","year":"2011","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.bja.2023.11.029_bib15","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1034\/j.1399-6576.2001.451005.x","article-title":"Danish anaesthesia allergy centre \u2013 preliminary results","volume":"45","author":"Garvey","year":"2001","journal-title":"Acta Anaesthesiol Scand"},{"key":"10.1016\/j.bja.2023.11.029_bib16","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.bja.2019.10.016","article-title":"Comparison of incidence of anaphylaxis between sugammadex and neostigmine: a retrospective multicentre observational study","volume":"124","author":"Orihara","year":"2020","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.bja.2023.11.029_bib17","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.jaip.2022.11.012","article-title":"Perioperative hypersensitivity evaluation and management: a practical approach","volume":"11","author":"Volcheck","year":"2023","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.bja.2023.11.029_bib18","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/ACI.0000000000000543","article-title":"Drug provocation testing: risk stratification is key","volume":"19","author":"Garvey","year":"2019","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.bja.2023.11.029_bib19","doi-asserted-by":"crossref","first-page":"E117","DOI":"10.1016\/j.bja.2019.01.002","article-title":"In\u00a0vitro diagnostic tests for perioperative hypersensitivity, a narrative review: potential, limitations, and perspectives","volume":"123","author":"Takazawa","year":"2019","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.bja.2023.11.029_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.668962","article-title":"Novel insights on MRGPRX2-mediated hypersensitivity to neuromuscular blocking agents and fluroquinolones","volume":"12","author":"Elst","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.bja.2023.11.029_bib21","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/j.1398-9995.2009.02193.x","article-title":"National pholcodine consumption and prevalence of IgE-sensitisation: a multicentre study","volume":"65","author":"Johansson","year":"2010","journal-title":"Allergy"},{"key":"10.1016\/j.bja.2023.11.029_bib26","doi-asserted-by":"crossref","first-page":"E38","DOI":"10.1016\/j.bja.2019.01.031","article-title":"Molecular mechanisms and pathophysiology of perioperative hypersensitivity and anaphylaxis: a narrative review","volume":"23","author":"Ebo","year":"2019","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.bja.2023.11.029_bib22","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.bja.2020.12.018","article-title":"Relationship of perioperative anaphylaxis to neuromuscular blocking agents, obesity, and pholcodine consumption: a case-control study","volume":"126","author":"Sadlier","year":"2021","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.bja.2023.11.029_bib23","unstructured":"Available from: www.gov.uk\/drug-device-alerts\/class-2-medicines-recall-various-marketing-authorisation-holders-pholcodine-containing-products-el-23-a-slash-09 (accessed 21 March 2023). Medicines and Healthcare products Regulatory Agency list of pholcodine-containing products"},{"key":"10.1016\/j.bja.2023.11.029_bib24","unstructured":"Available from: https:\/\/anaesthetists.org\/Home\/Resources-publications\/Safety-alerts\/Anaesthesia-emergencies\/Perioperative-allergy-network (accessed 21 March 2023). UK Perioperative Allergy Network statement on withdrawal of pholcodine-containing products"},{"key":"10.1016\/j.bja.2023.11.029_bib25","unstructured":"Available from: https:\/\/perioperativeallergy.com (accessed 21 March 2023). The UK Perioperative Allergy Network"}],"container-title":["British Journal of Anaesthesia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007091223006554?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007091223006554?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T01:51:40Z","timestamp":1740793900000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007091223006554"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S0007091223006554"],"URL":"https:\/\/doi.org\/10.1016\/j.bja.2023.11.029","relation":{},"ISSN":["0007-0912"],"issn-type":[{"value":"0007-0912","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pholcodine and allergy to neuromuscular blocking agents: where are we and how did we get here?","name":"articletitle","label":"Article Title"},{"value":"British Journal of Anaesthesia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bja.2023.11.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.bja.2023.02.033","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2023 Published by Elsevier Ltd on behalf of British Journal of Anaesthesia.","name":"copyright","label":"Copyright"}]}}